USAR heads into September with a fresh analyst endorsement pulling against a heavy short position and a stock that just shed 11% in a week.
The most notable development this week is Jefferies initiating coverage with a Buy rating and a $21 price target — essentially in line with where the stock closed Tuesday at $17.26. That is a far more cautious entry point than the broader analyst consensus. Eight analysts carry Buy-equivalent ratings, and the mean target runs to $35.56, implying more than 100% upside from current levels. The Street remains broadly constructive on USAR's thesis — a domestically integrated rare earth supply chain serving defense, EV, and robotics demand. But the Jefferies target is a notable outlier on the low end, and recent months brought a string of target cuts: Needham trimmed from $39 to $33 in late July; Roth Capital cut from $40 to $30 around the same time. The direction of travel among analysts who are already on board has been downward, even as the buy recommendations hold. Bears point to execution risk: production yield challenges at the NdFeB magnet plant, supply uncertainty post-2027, and a history of missed revenue estimates against a backdrop of negative earnings.
The lending market tells a story of sustained but not extreme short pressure. Short interest is running at 21.9% of the free float — a high structural level, but relatively flat over the past month (up less than 0.1%). The week-on-week change is essentially zero, suggesting shorts are neither adding aggressively nor covering. What has shifted is the borrow rate: cost to borrow has risen 25% over the week to 0.70%, and 28% over the past month. That is still a low absolute rate, meaning new shorts face limited friction entering positions. Availability is tighter than it looks on the surface — currently at 28% of short interest, down from above 50% just a week ago — though the 52-week low was near zero in August, when availability briefly collapsed to 0.14%. The current reading represents a loosening from those extreme lows, not a new tightening. Options positioning is leaning bullish: the put/call ratio of 0.54 is running almost 1.7 standard deviations below its 20-day average of 0.58, near the lower end of the past year's range. Calls are meaningfully outpacing puts, which contrasts with the weight of short interest still sitting in the stock.
The ORTEX short score of 66.9 ranks in the bottom 2nd percentile across all stocks on the short-score factor — flagging this as a name with notably elevated short-side pressure relative to the universe. Days-to-cover ranks in the 15th percentile, and availability in the 7th percentile. Together these signal that the short book is real and entrenched, not a passing position. Yet the 30-day EPS momentum score ranks in the 87th percentile, a sharp divergence: near-term estimate revisions are moving up even as the stock re-rates lower. That tension between improving forward estimates and a persistent short book is the central debate for USAR right now.
Two activists remain on the 13D register and are worth watching. Gutnick Mordechai Zev holds 6.8% as last disclosed — down from 16.7% at the previous filing — and Michael Blitzer filed a 13D/A showing 5.8%, reduced from 7.1%. Both have trimmed, and the direction of those disclosures matters: activist 13D holders reducing their stakes can signal waning conviction, though as always, positions can fall below 5% without a further filing. On the institutional side, BlackRock and State Street both added meaningfully as of their July 31 reports, and T. Rowe Price added over 6.2 million shares as of June 30 — a notable accumulation for a stock this size. That institutional buying provides a counterweight to the activist reductions. Insider data is stale (last trade reported January 29), so no fresh directional signal is available from that source.
The peer group offered no shelter this week. MP fell 10.7%, NB dropped 10.5%, TMC shed 10.2%, and CRML led declines at nearly 15%. USAR's 11% loss sits roughly in line with the group — this was a sector-wide reset, not a USAR-specific sell-off. The next earnings date is set for November 6, and the two most recent prints produced negative one-day reactions of 7.4% and 2.2% respectively. That pattern will be worth tracking as the quarter progresses and the Jefferies initiation gets absorbed by the market.
The next test for USAR is whether the Jefferies entry — cautious on the target but constructive on the name — draws fresh institutional interest at current levels, or whether the weight of a 22% short float and a sector still selling off continues to set the tone through the autumn.
See the live data behind this article on ORTEX.
Open USAR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
